C.DIFF BREAKTHROUGH: Genetic Lab to Share Gut Microbiome Discovery
Health News

C.DIFF BREAKTHROUGH: Genetic Lab to Share Gut Microbiome Discovery

Progenabiome, a genetic sequencing laboratory of the gut flora. Leading the way into the FUTURE by understanding the microbiome NOW. The quest for a new healthcare revolution!
Progenabiome, a genetic sequencing laboratory of the gut flora. Leading the way into the FUTURE by understanding the microbiome NOW. The quest for a new healthcare revolution!

“This data will change healthcare and make us more aware of our gut microbiome,” said Dr. Sabine Hazan-Steinberg, CEO and Founder of Progenabiome. “2500 years later, we’re proving Hippocrates right…everything starts in the gut.”

Dr. Hazan, a Malibu-based gastroenterologist, has 20+ years experience leading clinical trials, many for C.diff. When trials failed, she used fecal microbiota transplant (FMT), following advice from friend Dr. Neil Stollman, gastroenterologist at UCSF and East Bay Center for Digestive Health. She also followed great work by Dr. Thomas Borody, FMT pioneer and Centre for Digestive Diseases founder. Success post-FMT for recurrent C.diff suggested the microbiome holds many answers.

Knowing the C.diff microbe has existed for 10 million years, she questioned why it now takes 50,000 lives annually.

Dr. Sydney Finegold, infectious disease specialist who researched Autism/microbiome for 50 years, recommended she acquire a next-generation sequencer. When he passed in 2018, his books went to Hazan, hoping she could continue his legacy.

In January, she joined pathologist Dr. Brad Barrows and scientific director Dr. Andreas Papoutsis to launch Progenabiome. Their first run found non-toxigenic C.diff in every sample, including those not diagnosed with the disease. Preliminary data shows the C.diff microbe is not transmitted hand-to-mouth as previously believed. It is already in the gut and becomes toxic when something ingested triggers it.

Progenabiome will present this groundbreaking discovery at ACG 2019 (Poster 1027 / Booth 1931) and the 7th Annual International C.diff Conference November 6-7, 2019 in St. Louis.

Progenabiome is investigating the role of the gut flora in various diseases through 11 studies overlooked by New England IRB. Progenabiome’s Mission: to better understand, prevent, and treat diseases by analyzing specific genetic codes of 40 trillion gut microbes. Dr. Hazan believes the art of Medicine lies in our ability to see outside the box and recognize that all microbes and humans are unique.

For more: progenabiome.com /Facebook

Contact: Stephanie Davis, marketing@progenabiome.com

the microbiome
the microbiome diet
the human microbiome
the gut microbiome
the human gut
the gut microbiota

Health News

A Physician’s Role In A Changing 2020 Clinical Research Landscape

Dr. Hazan, Our Start!

Born in Morocco, Dr. Sabine Hazan has always had a dedication to understanding life. She sought a career in medicine and was accepted to medical school based on outstanding research on obesity conducted as an undergraduate.  She completed her residency at the University of Miami during the peak of the HIV epidemic, treating extremely ill patients at Jackson Memorial Hospital and in the local jail.  Here she was awarded two prizes for her research.  After residency Dr. Hazan became the first woman gastroenterology fellow at the University of Florida.  Here she completed a year of research and presented her findings in poster format at the American College of Gastroenterology National Meeting.  It was at that moment  that she was approached by the esteemed Dr. Neil Stollman. He told her that the future of medicine lies in the microbiome. For her exceptional work with visceral hyperalgesia she was awarded the Dean’s Research Award.  Dr Stollman is now an expert and leader on Fecal transplant and Clostridoides Difficile and serves on  the governing board of the  American College of Gastroenterology.

Following her fellowship, Dr. Hazan returned to Montreal and opened a practice in upstate New York, on the border.  Her work in this practice, comprised of 10 percent research and 90 percent private gastroenterology patients, brought many patients from across the border in Canada.  She was the only female gastroenterologist in a 80-mile radius, and this influx of Canadian patients brought to light for her the problems with socialized medicine in Canada.  These patients faced intolerable wait times for a visit with a gastroenterologist in Canada, and so visited Dr. Hazan in New York.  After meeting with the Prime Minister of Health, Dr. Hazan helped bring about a dual system in Canada, in which private practices co-exist with socialized medicine.  Her years of practice as a solo woman gastroenterologist brought her under the microscope on numerous occasions, facing scrutiny not encountered by her male colleagues.  

After the birth of her two children, Dr. Hazan and her husband Dr Alon Steinberg  moved to California.  Here she joined her sister, Dr. Lydie Hazan, at Axis Today Clinical Trials as a Sub Investigator, and began doing clinical trial research in California for the company in Beverly Hills.  She also joined a medical group as a private practitioner in Ventura.  However, her desire for innovation led her to establish thriving private practices in Malibu, Thousand Oaks, and Ventura. Still desiring to understand life, she started her own clinical trial company 16 years ago, Ventura Clinical Trials, and has been Principal Investigator and Sub Investigator in over 300 clinical trials.  Many of these trials were for Clostroides difficile infection (CDI), enough that through her impressive recruitment she became known as the Queen of C. difficile in the clinical trial community.  When her patients with Clostroides difficile did not respond to traditional or clinical trial therapies, she resorted to treatment with fecal microbiota transplant.  

 

As found on Youtube

The Microbiome